Daxdilimab targets and depletes plasmacytoid dendritic cells, whereas litifilimab targets BDCA2 receptors on plasmacytoid dendritic cells to downregulate them without causing depletion

From the articleBiogen's experimental lupus drug shows benefit against skin symptoms | ReutersAlso in In Phase 2 Trial, Daxdilimab Reduces Disease Activity in Moderate-to-Severe Discoid Lupus